Original time-to-event information on a composite renal outcome was retrievable from Kaplan–Meier curves of 12 major cardiovascular outcome trials, which were included in the analysis: three trials investigated GLP-1 receptor agonists (AMPLITUDE-O [41], LEADER [42, 43], and REWIND [44, 45]), nine SGLT2 inhibitors (CANVAS [46], CREDENCE [47], DAPA-CKD [48], DECLARE-TIMI 58 [49], EMPA-KIDNEY [50], EMPA-REG [51, 52], EMPEROR-PRESERVED [15, 53], EMPEROR-REDUCED [12, 53], and VERTIS-CV [54]). This evidence concerns the gene GLP1R and chronic kidney disease.